Effects of HMG-CoA reductase inhibitor on hemostasis

International Journal of Cardiology

Volumn 76, Issue 1, 2000, Pages 23-32

  Koh, Kwang Kon ^a  

^a Gachon University College of Medicine   (South Korea)

Author keywords

Atherosclerosis; Coagulation; Fibrinolysis; Lipid lowering therapy; Platelet; Viscosity

Indexed keywords

ATORVASTATIN; FIBRINOGEN; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPROSTANE; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; STATIN;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; FIBRINOLYSIS; HUMAN; PLASMA VISCOSITY; PRIORITY JOURNAL; REVIEW; THROMBOCYTE; THROMBOGENESIS;

EID: 0033767901     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(00)00325-9     Document Type: Article

References (98)

1. Randomized trial of cholesterol lowering in 4444 participants with coronary heart disease: the Scandinavian Simvastatin Survival Study
2. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
3. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
4. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS
5. The influence of pretreatment low density lipoprotein cholesterol concentrations on the effect of hypercholesterolemic therapy on coronary atherosclerosis in angiographic trials
6. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS)
7. Expert Panel Report of the National Cholesterol Education Program
8. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
9. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease
10. Identifying adults at increased risk of coronary disease: how well do the current cholesterol guidelines work?
11. Statins do more than lower cholesterol
12. Biological mechanisms for the clinical success of lipid-lowering in coronary artery disease and the use of surrogate end points
13. Direct vascular effects of HMG-CoA reductase inhibitors
14. Reduction in cardiovascular events during pravastatin therapy: pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program
15. Molecular bases of the acute coronary syndromes
16. Fibrinogen and risk of cardiovascular disease. The Framingham Study
17. Fibrinogen and factor VII in the prediction of coronary risk: results from the PROCAM study in healthy men
18. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study
19. Association of fibrinolytic parameters with early atherosclerosis: the ARIC Study
20. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction
21. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
22. Effects of hormone replacement therapy on coagulation and fibrinolysis in postmenopausal women
23. An enzyme cascade in the blood clotting mechanism and its function as a biochemical amplifier
24. Vascular-bed-specific hemostasis and hypercoagulable states
25. Tissue factor pathways of blood coagulation
26. Plasminogen activation and the regulation of pericellular proteolysis
27. Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells
28. The fast acting inhibitor of tissue-type plasminogen activator in plasma is also the primary plasma inhibitor of urokinase
29. Tissue factor and haemostasis
30. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque
31. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study
32. Association of hemostatic variables with prevalent cardiovascular disease and asymptomatic carotid artery atherosclerosis
33. Oxidized LDL enhances lipopolysaccharide-induced tissue factor expression in human adherent monocytes
34. Vastatins inhibit tissue factor in cultured human macrophages
35. Simvastatin reduces monocyte tissue-factor expression type IIa hypercholesterolaemia
36. Dietary lipid lowering reduces tissue factor expression in rabbit atheroma
37. Copper-induced tissue factor expression in human monocytic THP-1 cells and its inhibition by antioxidants
38. Decreased in vitro oxidizability of low-density lipoprotein in hypercholesterolemic patients treated with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors
39. Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages
40. Simvastatin decreases aldehyde production derived from lipoprotein oxidation
41. Enhanced in vitro oxidation of plasma lipoproteins derived from hypercholesterolemic patients
42. Tissue factor pathway inhibitor attenuates procoagulant activity and upregulation of tissue factor at the site of balloon-induced arterial injury in pigs
43. Presence of tissue factor pathway inhibitor in human atherosclerotic plaques is associated with reduced tissue factor activity
44. Anticoagulant activity of tissue factor pathway inhibitor in human plasma is preferentially associated with dense subspecies of LDL and HDL and with Lp(a)
45. Tissue factor pathway inhibitor and lipoproteins: evidence for association with and regulation by LDL in human plasma
46. Levels of factor VIIc associated with decreased tissue factor pathway inhibitor and increased plasminogen activator inhibitor-1 in dyslipidemias
47. Treatment with hydroxymethylglutaryl coenzyme A reductase inhibitors in hypercholesterolemia induces changes in the components of the extrinsic coagulation system
48. Effect of ω-3 fatty acids and simvastatin on hemostatic risk factors and postprandial hyperlipemia in patients with combined hyperlipemia
49. Tissue factor pathway inhibitor is expressed by human monocyte-derived macrophages. Relationship to tissue factor induction by cholesterol and oxidized LDL
50. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implication for consequences of plaque rupture
51. Coronary plaque erosion without rupture into a lipid core: a frequent cause of coronary thrombosis in sudden coronary death
52. Hyperlipidemia and coronary disease: correction of the increased thrombogenic potential with cholesterol reduction
53. Thromboxane biosynthesis, neutrophil and coagulation activation in type IIa hypercholesterolemia
54. Increased thromboxane biosynthesis in type IIa hypercholesterolemia
55. Relationship between prothrombin activation fragment F1+2 and serum cholesterol
56. Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia
57. Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile
58. The anti-thrombotic effects of statins
59. Platelet-dependent thrombin generation in patients with hyperlipidemia
60. Platelet function in hyperlipoproteinemia
61. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia
62. Effect of cholesterol on production of thromboxane B sub 2 by platelets in vitro
63. In vivo formation of 8-Epi-prostaglandin F2 alpha is increased in hypercholesterolemia
64. 2+ and membrane dynamics in patients with primary hypercholesterolemia: effects of pravastatin
65. Increased thrombotic vascular events after change of statin
66. Atorvastatin-induced severe thrombocytopenia
67. Thrombotic thrombocytopenic purpura and simvastatin
68. Relationship between plasma fibrinogen and coronary heart disease in women
69. Viscosity and ischemic heart disease
70. Effects of lovastatin therapy on plasminogen activator inhibitor-1 antigen levels
71. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia
72. Lovastatin alters blood rheology in primary hyperlipoproteinemia: dependence on lipoprotein(a)?
73. Effect of lovastatin on hemorheology in type II hyperlipoproteinemia
74. Effects of long-term treatment with lovastatin on the clotting system and blood platelets
75. Lovastatin therapy in hypercholesterolemia: effect on fibrinogen, hemorheologic parameters, platelet activity, and red blood cell morphology
76. Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia
77. Hypercoagulable state in patients with hypercholesterolemia: effects of pravastatin
78. Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia
79. Hemorheologic and coagulative pattern in hypercholesterolemic subjects treated with lipid-lowering drugs
80. Atorvastatin: an effective lipid-modifying agent in familial hypercholesterolemia
81. Effect of atorvastatin on plasma fibrinogen
82. β-Fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction: the ECTIM Study
83. Intraindividual variability of fibrinogen levels and cardiovascular risk profile
84. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial
85. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women
86. Attenuation of the synthesis of plasminogen activator inhibitor type I by niacin: a potential link between lipid-lowering and fibrinolysis
87. Comparison of bezafibrate versus lovastatin for lowering plasma insulin, fibrinogen, and plasminogen activator inhibitor-1 concentrations in hyperlipemic heart transplant patients
88. Elevated plasma levels of vascular endothelial cell markers in patients with hypercholesterolemia
89. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid
90. Lipoprotein(a) regulates plasminogen activator inhibitor-1 expression in endothelial cells
91. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells
92. Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids
93. Effect of fluvastatin on lipids and fibrinolysis in coronary artery disease
94. Vascular effects of estrogen and cholesterol-lowering therapies in hypercholesterolemic postmenopausal women
95. Lipoprotein(a) as a risk predictor for cardiac mortality in patients with acute coronary syndromes
96. HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels
97. Effects of one year of treatment with pravastatin, an HMG-CoA reductase inhibitor, on lipoprotein(a)